Envista Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Envista raised its medium-term financial outlook, driven by strong execution in growth, operations, and innovation across all business segments. New product launches, digital transformation, and disciplined capital allocation are fueling above-market performance, with continued investment in R&D and productivity initiatives supporting sustainable growth.
-
Leadership highlighted improved financials and market share gains, with consumables and diagnostics leading growth. China’s VBP reforms are causing short-term revenue impacts but are expected to strengthen the company’s position long-term, especially in ortho and implants.
-
Q2 2026 saw 5% core growth, 28% adjusted EBITDA growth, and 58% EPS growth, with strong performance across all segments and geographies. Guidance for 2026 was raised, reflecting continued momentum, robust cash flow, and margin expansion.
-
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals passing by majority vote. A quorum was present, and no stockholder questions were submitted during the Q&A session.
-
Q1 2026 saw double-digit sales, adjusted EBITDA, and EPS growth, driven by broad-based segment and geographic performance. Operational improvements and continued investment in innovation supported margin expansion, while the board authorized a $300 million share repurchase and reaffirmed 2026 guidance.
-
Dental market growth is accelerating, supported by strong demand, innovation, and favorable macro trends. Key segments like Spark and implants are showing robust performance, with new product launches and operational improvements driving profitability. Pricing and restructuring actions are supporting financial targets.
Fiscal Year 2025
-
Q4 and full-year 2025 saw double-digit EBITDA and EPS growth, broad-based gains across all segments, and strong cash flow conversion. 2026 guidance targets continued core growth, margin expansion, and robust free cash flow, with tariff and China market risks noted.
-
Dental market growth remains stable, with consumables and orthodontics leading consistent performance. Spark and implant businesses benefit from innovation, automation, and targeted investments, while new product launches and AI adoption drive diagnostics. Strong cash flow supports organic growth, M&A, and shareholder returns.
-
Q3 2025 saw strong revenue and earnings growth, with core growth at 9% (5% excluding Spark deferral), adjusted EBITDA margin up 540 bps to 14.5%, and adjusted EPS more than doubling year-over-year. Full-year guidance was raised, and Spark aligners reached profitability.
-
Q2 2025 saw strong revenue and EPS growth, margin expansion, and broad-based gains across all segments and geographies. Full-year guidance was raised for both core revenue and EPS, with stable dental market conditions and effective tariff mitigation.
-
Dental market fundamentals remain strong, with orthodontics and consumables leading growth. Strategic investments and operational improvements are driving performance, while tariff risks are being managed through supply chain flexibility. Spark is on track for profitability, with automation supporting margin expansion.
-
Q1 2025 saw stable core growth, margin performance in line with expectations, and adjusted EPS slightly above guidance. Tariff and FX headwinds were offset by price and productivity gains, with mitigation actions expected to benefit the second half. Guidance for 2025 is maintained.
-
Management outlined a focused strategy on growth, operational excellence, and people, with new medium-term financial targets of 2%-4% core growth, 4%-7% Adjusted EBITDA growth, and 7%-10% EPS growth. Recent investments and innovation have returned key businesses to growth, while a disciplined capital allocation approach supports shareholder value.
-
Dental market growth is expected to normalize after recent softness, with stable conditions and strong long-term drivers. Strategic investments in commercial operations, innovation, and training are set to accelerate growth, especially in specialty segments and key regions.
Fiscal Year 2024
-
Q4 and full-year 2024 results met expectations, with core growth stabilizing and strong free cash flow. 2025 guidance projects 1%-3% core growth, ~14% EBITDA margin, and EPS of $0.95-$1.05, supported by operational improvements, restructuring savings, and a $250 million share repurchase program.
-
The dental market is stable but slow, with basic procedures steady and higher-ticket items lagging. Inventory normalization and macro factors like interest rates are shaping near-term results, while China’s VBP and local manufacturing are key strategic focuses. Growth investments, especially in implants and digital, are expected to drive future margin expansion.
-
Q3 2024 results met expectations, with underlying performance stable but reported results lower due to Spark revenue deferral and channel inventory actions. Guidance for full-year core growth and margins was reaffirmed, with Q4 expected to return to growth.
-
Q2 2024 saw a 3.2% core sales decline and a $1.2B non-cash impairment, but free cash flow rose 41%. Strategic actions and investments are expected to drive a return to growth in Q4, with normalized 2024 performance targeted at ~1% core growth and ~14% EBITDA margin.